Search Results

You are looking at 101 - 110 of 298 items for :

Clear All
Full access

Margaret Tempero

HER2 amplification. I was thrilled. This was actionable and gave us another option down the road. So when the time came, after standard therapy stopped working, we were able to get both trastuzumab and pertuzumab. We started treatment, but it didn

Full access

standards of care to their practice and health care setting. Studies show that triple-negative breast cancers (negative for hormone receptors and HER2) have a significantly more aggressive clinical course with increased rates of local recurrence and

Full access

Christopher E. Desch

– 506 . 9. Norum J Risberg T Olsen JA . A monoclonal antibody against HER-2 (traztuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis . Ann Oncol 2005 ; 16 : 909 – 914 . 10. Mayor S . NICE approves

Full access

1056 0131054 10.6004/jnccn.2015.0129 NCCN: The Future is Bright Silver Samuel M. MD, PhD 9 2015 13 13 9 9 1058 1058 1059 1059 0131058 10.6004/jnccn.2015.0130 HER2 -Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a

Full access

Jaffer A. Ajani, Thomas A. D’Amico, Khaldoun Almhanna, David J. Bentrem, Stephen Besh, Joseph Chao, Prajnan Das, Crystal Denlinger, Paul Fanta, Charles S. Fuchs, Hans Gerdes, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kory Jasperson, Rajesh N. Keswani, Lawrence R. Kleinberg, W. Michael Korn, Stephen Leong, A. Craig Lockhart, Mary F. Mulcahy, Mark B. Orringer, James A. Posey, George A. Poultsides, Aaron R. Sasson, Walter J. Scott, Vivian E. Strong, Thomas K. Varghese Jr, Mary Kay Washington, Christopher G. Willett, Cameron D. Wright, Debra Zelman, Nicole McMillian and Hema Sundar

, and specific requirements for local control. Assessment of HER2/neu Overexpression Human epidermal growth factor receptor 2 ( HER2 ) gene and/or HER2 protein expression has been implicated in the development of gastric and EGJ

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

response to therapy (e.g., hormone receptors and human epidermal growth factor receptor 2 [HER2]). These factors are determined through examining excised tissue and are provided in a written pathology report. Accurate pathology reporting requires the

Full access

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian and Lenora A. Pluchino

in accordance with guidelines for gastric cancer. Principles of Biomarker Testing Presently, molecular testing for HER2 status, microsatellite instability status, and programmed death-ligand 1 (PD-L1) expression are used in the clinical management of

Full access

Holly Dushkin and Massimo Cristofanilli

characteristics typical of IBC are associated with poor outcome, including high S-phase fraction, high grade, aneuploidy, lack of estrogen and progesterone receptor expression, and overexpression of human epidermal growth factor receptor 2 (HER2). 10 – 12

Full access

Ingrid A. Mayer

. Bardia A Dickler MN Mayer IA . Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive, HER2-breast cancer [abstract] . Presented at the 2014 San Antonio

Full access

Damien Urban, Danny Rischin, Christopher Angel, Ieta D’Costa and Benjamin Solomon

GCDFP-15, CK7, and AR, and negative staining for c-kit, CK20, and HER2. The patient received 60 Gy of postoperative radiotherapy in 30 fractions and then adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP). During the third